Hate to state the obvious but you said the same thing last week about $4.70 and that prediction proved false. I think it would be best not to give advice to others when you have no idea, nor does anyone else for that matter, what is going to happen with this stock.
I strongly believe in gap fills with Gern, but not this one because there was breakaway volume on historic news of CRs in a disease with no prior CRs. That is a major proof of concept for I'm testator and portends blockbuster potential as it now appears to work both for ET and MF and possibly we will learn that AML is added to the list. OTHER INDICATIONS ARE LIKELY!